Bayer's Blockbuster Eylea Faces Patent Expiration: A Strategic Move for Pipeline Revitalization

German pharmaceutical giant Bayer has undertaken a pipeline transformation to address the impending patent expiration and declining sales of its key ophthalmic drug, Eylea. In 2025, Eylea generated €3.1 billion (approximately $3.7 billion) in sales within Bayer's territories, making it the company's top-selling product. However, it faces a looming threat from biosimilar competition, which could significantly impact its revenue. To maintain its leadership in the ophthalmology market, Bayer has decided to acquire Perfuse Therapeutics, a San Francisco-based biotech company. This acquisition represents a strategic move by Bayer to secure a next-generation alternative to fill the void left by Eylea.

Clinical Value of Innovative Endothelin Receptor Antagonist PER-001

The core asset of the acquisition, PER-001, is an innovative first-in-class drug candidate administered as an intravitreal implant. This compound is a selective endothelin receptor-A antagonist that blocks the action of endothelin-1, which induces vasoconstriction and cell death. It aims to improve intraocular blood flow and protect retinal cells in patients with glaucoma and diabetic retinopathy. In a Phase 2 clinical trial last year, it demonstrated significant efficacy, including improved visual field sensitivity and reduced macular ischemia.

Bayer's Risk-Diversified Financial Strategy Through Conditional Agreement

Although the total transaction amount is $2.4 billion, Bayer has designed a financial structure to diversify its risk. An upfront payment of $300 million will be made, with the remaining $2.15 billion paid in milestones based on clinical progress and approval. Given the high failure rate of drugs in the Phase 2 stage, this performance-based payment structure minimizes initial risk. This reflects Bayer's intention to secure Perfuse's technology while minimizing financial uncertainty during the development process.

Advantages of the 6-Month Sustained-Release Formulation Maximizing Patient Convenience

A key advantage of PER-001 is its sustained-release formulation, which requires an injection into the eye only once every six months. Existing anti-VEGF injections require patients to receive direct injections into the eye every 1-2 months, causing significant physical discomfort and inconvenience. In contrast, the 6-month implant formulation improves patient convenience and compliance, ultimately leading to better outcomes. This has the potential to address unmet needs for both healthcare professionals and patients, transforming the paradigm of ophthalmic treatment.

Opportunity to Capture a Large Global Market and Future Challenges

The global market for glaucoma treatments is approximately $9 billion in 2025, and the market for diabetic retinopathy treatments is approaching $10 billion. The number of patients with these conditions is increasing rapidly each year due to aging populations and an increase in diabetic patients, leading to growing unmet needs. If Bayer can demonstrate the efficacy and long-term safety of PER-001 in future Phase 3 and later trials, it can capture a significant share of the global market. If successfully commercialized, it will fill the gap left by Eylea and become a key growth driver for Bayer's ophthalmology portfolio.